BiotechTube
Diagnostic BioSystems

Diagnostic BioSystems

Mountain View, United States· Est.
dbiosys.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Diagnostic BioSystems is a long-established, privately-held player in the global immunohistochemistry (IHC) diagnostics market. The company provides a comprehensive suite of IHC reagents, detection systems, and automated staining instruments used in clinical pathology labs for cancer diagnosis and research. With a focus on quality and customer support, DBS serves both U.S. and international markets through a network of distributors. Its strategy involves continuous product innovation, as evidenced by new antibody launches and its multiplex IHC capabilities, aiming to support pathologists in delivering precise diagnostic results.

Oncology

Technology Platform

Portfolio of immunohistochemistry (IHC) reagents, detection systems, and automated staining instruments for anatomic pathology. Includes primary antibodies, chromogens, retrieval solutions, and the DBS Highlighter™ 360 Autostainer and Montage Opus365™ systems. Capabilities in multiplex IHC.

Opportunities

Growth is driven by the expanding global IHC market, increasing cancer diagnostics, and the trend toward lab automation.
The company can capitalize on demand for cost-effective, high-quality reagent alternatives and expand its footprint in emerging international markets.
Advancing its multiplex IHC offerings presents an opportunity in the growing field of complex biomarker analysis.

Risk Factors

Faces intense competition from large, entrenched diagnostics corporations.
Regulatory hurdles for IVD products in the U.S.
and internationally add complexity and cost.
The long-term landscape may be challenged by technological shifts towards molecular diagnostics and digital pathology.

Competitive Landscape

Operates in a highly competitive market dominated by global giants like Roche (Ventana), Agilent (Dako), and Bio-Rad. Competes primarily on product quality, price, customer service, and a broad catalog of antibodies. Also faces competition from other specialized IHC reagent suppliers and low-cost manufacturers.

More companies in Diagnostics & Precision Medicine →More companies in United States →